JUNS

distress 4/10 · elevated risk

$0.16-9%today-95% from 52w high

jupiterneurosciences.com5 employeesFounded 2016Jupiter, FLBiotechnology

Revenue

pre-revenue

Liquidity

$0M

Runway

—

Shares 1y

+4%

Price & events

-82.9% over 6M

CatalystRating changeDilutionFinancingdashed = today

-8.6%

-8.0%

-32.2%

-58.5%

-82.0%

-90.8%

—

-97.1%

All

Overview

Market Cap: $5.80M
Volume: 1.52M
52 Week Range: $0.16 – $2.97
Total Shares: 36.28M
Float Shares: 22.50M
Short %: 2.72%
% Held by Insiders: 37.91%
% Held by Institutions: 3.95%
RVOL: 0.10x

Pipeline · 0 trials · 0 upcoming

Readout	Phase	Drug	Indication	Enroll	Status
No pipeline trials tracked.

Catalyst news & presentations · 2

2026-05-19partnershipALA-002 · Exclusive U.S. licensing rights to next-generation MDMA formulation from PharmAlaSEC 8-K
2026-02-26warning letterNasdaq notified the company of non-compliance with minimum bid price requirement (Rule 5550(a)(2)) and market value of listed securities requirement (Rule 5550(b)(2))SEC 8-K

Approved drugs (0)

none — clinical-stage

Capital structure — dilution & financing

Shares out: 36,281,252 · 11 offerings/1y · 3 PIPEs

2026-07-218-Kprivate_placement
2026-07-21424B3offering
2026-07-07EFFECTshelf_effective
2026-06-30424B3offering
2026-06-26S-1shelf_registration
2026-06-22424B3offering
2026-06-05424B3offering

🔒 Positioning — Pro

Short interest / days-to-cover, insider buys & sells.

Upgrade to Pro

🔒 Top holders — Pro

Institutional ownership + quarter-over-quarter accumulation/trimming.

Upgrade to Pro

Wall St ratings

no consensus

no recent rating changes

Competitors

none identified